Welcome to our dedicated page for Zhongchao news (Ticker: ZCMD), a resource for investors and traders seeking the latest updates and insights on Zhongchao stock.
Zhongchao Inc. (NASDAQ: ZCMD) is a Cayman Islands holding company whose PRC operating entities are described as a platform-based internet technology business focused on patients with oncology and other major diseases, as well as online medical education. The ZCMD news feed highlights how the company’s activities in China intersect with cancer care, chronic disease management, health education, and capital markets disclosures.
News about Zhongchao frequently covers patient management and medication assistance projects. Company announcements describe initiatives for breast cancer patients, lung cancer patients, and individuals with systemic lupus erythematosus, including disease management services, patient-reported outcome-based models, and free medication programs for low-income patients. These projects often involve collaborations with hospitals, pharmacies, pharmaceutical enterprises, non-profit organizations, and public health foundations.
Another recurring theme in Zhongchao’s news is its role in professional and public health education. Releases describe the MDMOOC platform for healthcare professionals, the Digital Online Education Platform for Common Diseases Clinical Diagnosis and Treatment, and partnerships with the Ximalaya audio platform to deliver cancer education series such as “Let’s Talk About Tumors.” These items illustrate how the company uses digital channels to share medical knowledge with both clinicians and the general public.
Investors following ZCMD news will also see updates on pharmaceutical services and capital market actions, including the integration of Naiditawei® (Oseltamivir Phosphate Capsules) into listed online procurement programs in multiple Chinese regions, and corporate actions such as a 1-for-10 share consolidation aimed at maintaining Nasdaq Capital Market listing compliance. For ongoing developments in these areas, the Zhongchao news page aggregates company press releases and related coverage in one place.
Zhongchao Inc. (NASDAQ: ZCMD) reported robust financial results for the first half of 2020, with revenues up 21.1% to $8.46 million and operating income rising 49.2% to $1.88 million, driven by patient-aid projects and COVID-19 training courses. However, net income attributable to shareholders fell 15.7% to $1.46 million due to reduced government subsidies and higher taxes, leading to a decline in earnings per share from $0.08 to $0.06. Overall, the company maintains a positive outlook, expecting continued revenue growth in the second half of 2020.
Zhongchao Inc. (NASDAQ: ZCMD) announced its continued partnership with the European Wound Management Association (EWMA) to deliver advanced workshops on wound care and rehabilitation in China. Starting on September 11, 2020, the workshops will provide physicians with a comprehensive curriculum, including a core and advanced course in wound management. Participants can earn an EWMA certificate upon completion. In recognition of COVID-19 health workers, Zhongchao is waiving fees for eligible physicians.
Zhongchao Inc. (NASDAQ: ZCMD) announced a partnership with the China Association of Health Promotion and Education to develop live interactive courses aimed at promoting the Global Initiative for Chronic Obstructive Lung Disease (GOLD) in China. These courses are designed to enhance the clinical practices of healthcare professionals by providing practical guidelines on COPD management. Available on the MDMOOC platform, the programs feature diverse educational formats, including articles, case studies, and expert interviews. This initiative aims to increase awareness and improve patient outcomes related to COPD in the region.
Zhongchao Inc. (NASDAQ: ZCMD) announced the renewal of its contract with Johnson & Johnson (China) Limited, extending their partnership in healthcare services, training, and education. This collaboration, ongoing since 2017, capitalizes on Johnson & Johnson's significant presence in the Chinese market, including multiple R&D centers and manufacturing facilities. As the Chinese healthcare sector continues to grow, Zhongchao aims to leverage its relationship with J&J to capture market opportunities.
Zhongchao Inc. (NASDAQ: ZCMD) has partnered with the China Health Promotion Association and major pharmaceutical companies to launch a multi-year online education project focused on primary liver cancer. The initiative aims to implement national treatment guidelines and enhance professionals' knowledge in screening, diagnosis, and management of liver cancer. Since its launch in March 2020, over 145,000 medical professionals have participated in 12 training sessions, with more planned for the future.
On July 10, 2020, Zhongchao Inc. (NASDAQ: ZCMD) announced the co-organization of a virtual panel session on gastroenterology, part of the China-Russia-Near East Academic Dialogue. Held on June 30, 2020, the event featured prominent gastroenterologists from China, Russia, Lebanon, and Jordan and attracted over 36,000 participants. This follows another successful session on neonatology with 23,000 attendees. Chairman Weiguang Yang emphasized the importance of digital transformation in healthcare amidst COVID-19, expressing commitment to future collaborative events.
Zhongchao Inc. (NASDAQ: ZCMD) has officially launched a new line of patient management services branded as Zhongxun. This initiative expands its existing platforms, including MDMOOC and Sunshine Health Forums. The services will integrate online and offline approaches, collaborating with hospitals, pharmacies, and insurance companies to provide comprehensive patient management solutions. Chairman James Yang anticipates that Zhongxun will drive significant future growth, leveraging China's expanding healthcare market and technology advancements.